Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Sarepta Therapeutics, Inc. (SRPT)GlobeNewsWire • 07/13/26
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout24/7 Wall Street • 07/10/26
Sarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/08/26
All You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to BuyZacks Investment Research • 06/08/26
Why Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report?Zacks Investment Research • 06/05/26
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare ConferenceBusiness Wire • 05/13/26
Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook MaintainedZacks Investment Research • 05/07/26
Sarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy?Investors Business Daily • 05/07/26
Sarepta Therapeutics (SRPT) Reports Q1 Earnings: What Key Metrics Have to SayZacks Investment Research • 05/06/26
Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top EstimatesZacks Investment Research • 05/06/26
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate DevelopmentsBusiness Wire • 05/06/26
Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • 04/29/26